DV
Dividend Vision

PYXS — Pyxis Oncology Inc

Pyxis Oncology Inc (PYXS)

Total return is -77.2% over the past 4.8 years, 166.3 points behind SPY at 89.1%. Its deepest 1-year drawdown was 80.1%.

Pyxis Oncology is a clinical-stage biopharmaceutical company developing therapeutics for solid tumors, including antibody-drug conjugates, immunotherapies, and other oncology candidates in Phase 1 and Phase 2 clinical trials. The company does not currently distribute dividends. Pyxis Oncology appeals to investors seeking exposure to early-stage oncology development with no current income component.

PYXS key facts

Asset type
Stock
Asset class
Equity
Inception date
10/08/2021
Last close
$3.01
Market cap
$141,282,720
Average volume
701400.0
Beta
1.306
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.29